Benzinga · Jul 17, 2026
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In Shares
- Sec Filing
NASDAQ · TVRD
Healthcare · Biotechnology
$1.18
Down-$0.08 (-6.78%)
Updated Nov 17, 2026, 1:19 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TVRD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
TVRD closed at $1.18 after 20 trading sessions, up 21.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $1.16 | $1.18 | $1.08 | $1.18 | 75.66K |
| Nov 12, 2026 | $1.30 | $1.30 | $1.145 | $1.155 | 167.03K |
| Nov 11, 2026 | $1.40 | $1.61 | $1.26 | $1.34 | 459K |
| Nov 10, 2026 | $1.39 | $1.53 | $1.31 | $1.41 | 552.32K |
| Nov 9, 2026 | $0.96 | $1.61 | $0.9577 | $1.41 | 4.59M |
| Nov 6, 2026 | $0.8571 | $0.98 | $0.8469 | $0.9578 | 55.77K |
| Nov 5, 2026 | $0.87 | $0.882 | $0.8101 | $0.8645 | 177.13K |
| Nov 4, 2026 | $0.819 | $0.889 | $0.8048 | $0.8614 | 50K |
| Nov 3, 2026 | $0.83 | $0.8899 | $0.7961 | $0.8349 | 93.11K |
| Nov 2, 2026 | $0.826 | $0.85 | $0.79 | $0.8053 | 94.91K |
| Oct 30, 2026 | $0.8677 | $0.9284 | $0.7729 | $0.7928 | 154.88K |
| Oct 29, 2026 | $0.89 | $0.9151 | $0.85 | $0.863 | 111.91K |
| Oct 28, 2026 | $0.8403 | $0.9272 | $0.8403 | $0.8872 | 86.1K |
| Oct 27, 2026 | $0.831 | $0.8998 | $0.831 | $0.8653 | 72.75K |
| Oct 26, 2026 | $0.94 | $0.97 | $0.842 | $0.8421 | 139.58K |
| Oct 23, 2026 | $1.0702 | $1.0702 | $0.9201 | $0.94 | 108.87K |
| Oct 22, 2026 | $1.01 | $1.0499 | $0.9722 | $0.9722 | 55.41K |
| Oct 21, 2026 | $1.02 | $1.09 | $1.00 | $1.02 | 137.1K |
| Oct 20, 2026 | $1.03 | $1.0764 | $0.97 | $0.992 | 195.19K |
| Oct 19, 2026 | $1.01 | $1.0279 | $0.9687 | $0.97 | 201.34K |
The latest Smart Investors Daily articles mentioning TVRD.
Company
Market Activity
Research & News
TVRD research
Company profile and research snapshot.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | Chardan Capital | Buy | — |
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 8, 2026 | Raymond James | Outperform | — |
| Jul 7, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 17, 2026
- Sec Filing
Benzinga · Jul 9, 2026
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose
Benzinga · Jul 9, 2026
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.
Benzinga · Jul 9, 2026
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning TVRD.